Last reviewed · How we verify
IGI, 10%
IGI is an immunoglobulin-based therapeutic that modulates immune function through Fc receptor engagement.
At a glance
| Generic name | IGI, 10% |
|---|---|
| Also known as | TAK-339, Gammagard Liquid, KIOVIG |
| Sponsor | Takeda |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IGI appears to be an investigational immunoglobulin product in development by Takeda. The 10% formulation likely refers to a concentration or dosing specification. As a Phase 3 asset with limited public disclosure, the precise molecular mechanism and target remain proprietary, though immunoglobulin therapeutics typically work through Fc receptor binding to modulate immune cell activation and antibody-dependent cellular responses.
Approved indications
Common side effects
Key clinical trials
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) (PHASE3)
- A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants (PHASE3)
- A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) (PHASE3)
- Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP (PHASE3)
- A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants (PHASE1)
- Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects (PHASE3)
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGI, 10% CI brief — competitive landscape report
- IGI, 10% updates RSS · CI watch RSS
- Takeda portfolio CI